Table 2 Demographic and clinical characteristics of all patients

Age (years), median (IQR)

9.6 (7.2–13.0)

Female sex, n (%)

63 (46)

Weight (kg), median (IQR)

41.5 (26.6–61.7)

Race/Ethnicity, n (%)

Asian

4 (3)

White non-Hispanic

33 (24)

Hispanic

50 (36)

Black non-Hispanic

49 (36)

Other

2 (1)

Comorbidities, n (%)

Any co-morbidities

60 (43)

Asthma

19 (32)

Obesity

18 (30)

Other (anemia, hydronephrosis, ADHD, autism)

38 (63)

Severity of MIS-C, n (%)

Moderate

34 (25)

Severe

75 (54)

Organ support

Respiratory support, n (%)

74 (54)

Nasal cannula or venturi mask

44 (59)

High flow nasal cannula

18 (24)

Continuous or bi-level positive airway pressure

4 (5)

Intubation

8 (11)

Duration of intubation (days), median (IQR)

5.2 (4.1-6.0)

Duration of all respiratory support (days), median (IQR)

3 (1–6)

Vasoactive support, n (%)

69 (50)

Duration of vasoactive use (hours), median (IQR)

20.6 (10.4–48.3)

Echo findings

Presence of LV dysfunction, n (%)

34 (25)

LV shortening fraction (%), median (IQR)

32 (28–36)

Coronary artery aneurysm, n (%)

12 (9)

Immunomodulator therapy

IVIG, n (%)

129 (93)

Second dose of IVIG, n (%)

10 (7)

Methylprednisolone, n (%)

136 (99)

Anakinra, n (%)

57 (41)

Duration of anakinra (days), median (IQR)

5.5 (4.0-6.2)

Outcomes

Fever duration during admission (days), median (IQR)

1.0 (1.0–2.0)

ICU stay, n (%)

90 (65)

Length of ICU stay (days), median (IQR)

2.0 (1.4–4.9)

Length of hospital stay (days), median (IQR)

6.3 (4.2–8.7)